Physician profile
Jon M Mcrae
NPI 1700890274
$2,883.74
in general payments reported to CMS, 2019-2025
34 companies · $398 in 2025
The $398 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $351 · 2020: $316 · 2021: $339 · 2022: $232 · 2023: $510 · 2024: $737 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,644.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $388.88 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $274.34 | 2019-2025 | Seglentis, Livalo, Zoryve |
| Pfizer INC. | $226.16 | 2021-2025 | |
| Novo Nordisk INC | $223.31 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $177.31 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Teva Pharmaceuticals USA, INC. | $165.42 | 2019-2020 | |
| Exact Sciences Corporation | $156.10 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $144.43 | 2020-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $142.78 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Astellas Pharma US INC | $142.77 | 2019-2024 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $101.68 | 2023 | |
| Amgen INC. | $84.92 | 2019-2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $81.77 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $69.50 | 2020-2025 | Verquvo, Gardasil 9, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.43 | 2019-2025 | Xifaxan |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $49.48 | 2021 | |
| Lundbeck LLC | $47.21 | 2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $37.70 | 2020-2021 | |
| Corcept Therapeutics | $37.49 | 2024 | Korlym |
| Avanir Pharmaceuticals, INC. | $33.16 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $32.63 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.67 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.31 | 2025 | Caplyta |
| Ardelyx, INC. | $18.61 | 2024 | Ibsrela |
| Biohaven Pharmaceutical Holding Company LTD. | $18.46 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.37 | 2020 | |
| Sanofi-Aventis U.S. LLC | $17.16 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.50 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $14.45 | 2024 | Nuedexta |
| Ironwood Pharmaceuticals, INC | $14.28 | 2021 | |
| Amarin Pharma, INC. | $13.74 | 2019 | |
| Philips North America LLC | $13.61 | 2024 | (Ck7) Extended Holter |
| Allergan, INC. | $11.11 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Mcrae listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.